Rydapt 25 (Midostaurin Capsule) 25mg

RYDAPT 25mg capsules contain midostaurin, a prescription medication used to treat certain types of cancer. It belongs to a class of drugs known as kinase inhibitors. Store at room temperature away from moisture and heat.

Strength

25mg

Pack Size

56s

Storage

Ambient

Manufacturer / TM Owner

NOVARTIS PHARM CORP

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Midostaurin is used to treat adults with aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia. It is also used in combination with other medicines to treat acute myeloid leukemia (AML) in adults who have a specific genetic mutation. Midostaurin works by blocking certain proteins that help cancer cells grow.

Side Effects

Common effects of midostaurin may include nausea, vomiting, diarrhea, or fatigue. Some people experience decreased appetite, swelling in the hands or feet, or shortness of breath. These effects are often temporary and may lessen as the body adjusts to the medication.

Precautions & Warnings

Handle midostaurin capsules with care to avoid skin contact or inhalation of powder. Wash hands thoroughly after handling. Keep capsules in their original packaging until ready to use. Avoid opening or crushing capsules unless directed by a healthcare provider.

Avoid Interactions

Midostaurin may interact with other medications, including strong CYP3A4 inhibitors or inducers, which can affect how it works. Avoid grapefruit products while taking this medication. Alcohol and certain dietary supplements may also interact; consult a healthcare provider before combining therapies.

Frequently Asked Questions

RYDAPT 25mg is used to treat certain types of cancer, including aggressive systemic mastocytosis and acute myeloid leukemia with a specific genetic mutation.

Store RYDAPT capsules at room temperature, away from moisture and heat. Keep them in the original packaging until ready to use.

Midostaurin may interact with other drugs; consult a healthcare provider before combining therapies, especially CYP3A4 inhibitors or inducers.

Common side effects may include nausea, vomiting, diarrhea, fatigue, or decreased appetite. These effects are often temporary.

Handle capsules carefully to avoid skin contact or inhalation of powder. Wash hands thoroughly after handling.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.